2017-11-15T11:51:35-06:00 2016-12-31 521855942 Tate and Tryon 2021 L Street NW Suite 400 Washington DC 20036 990 2016-01-01 133905508 FOOD ALLERGY RESEARCH & EDUCATION INC FOOD 7036913179 7925 JONES BRANCH DRIVE No 1100 MCLEAN VA 221025303 SANDEEP DHAR CFO 7036913179 2017-11-15 1 Elizabeth Heller P00397829 2022932200 216.59.105.130 2017-11-15 11:51:31 ES P DA39A3EE5E6B4B0D3255BFEF95601890AFD80709 8B6C6DF7A8E3B84B5AE7D1943EC3750B5C691B8F 2016 2017-02-10 21:41:12Z JAMES BAKER MD 7925 JONES BRANCH DRIVE No 1100 MCLEAN VA 221025303 54803305 0 X WWW.FOODALLERGY.ORG X 1998 NY FARE's mission is to improve the quality of life and the health of individuals with food allergies, and to provide them hope through the promise of new treatments. 21 20 62 246 25000 -2600 12086613 11577982 73950 159574 7675829 -4946668 -727125 -420642 19109267 6370246 7301480 2873428 0 0 5658318 5616459 0 0 2056573 2998789 3438742 15958587 11928629 3150680 -5558383 63531340 57090740 6434026 5551809 57097314 51538931 X Food Allergy Research & Education (FARE) is the nation's leading advocacy organization working on behalf of the 15 million Americans with food allergies, including all those at risk for life threatening anaphylaxis. FARE's mission is to improve the quality of life and the health of individuals with food allergies, and to provide them hope through the promise of new treatments. Our work is organized around three core tenets: Life - supporting the ability of individuals with food allergies to live safe, productive lives with the respect of others through our education and advocacy initiatives; health - enhancing the access of individuals with food allergies to state-of-the art diagnosis and treatment; and hope - encouraging and fund research in both industry and academia that promises new therapies to improve the everyday lives of those living with food allergies. 0 0 3844293 2732436 SEE SCHEDULE OREsearch:FARE Clinical NetworkThe cornerstone of our efforts was the launch of the FARE Clinical Network ('FCN') in 2015 with 24 centers of excellence across the Unites States. The FCN sites are changing the face of food allergy research by raising the quality of care for food allergic patients nationwide, by reducing discrepancies in care among providers, and by making comprehensive care available for all patients with food allergies. FCN sites are helping parents, caregivers and patients identify centers that provide clinical and sub-specialty food allergy services of the highest quality and that are leaders in rapidly applying new evidence-based knowledge. Importantly, FCN centers are accelerating drug development for food allergy by enhancing sites' infrastructure and capabilities to perform crucial late stage trials and providing the basis for a national food allergy patient registry and bio-repositories. FARE added five new sites in 2016. FARE's annual investment in the network in 2016 was $2.3mm for 28 sites (one site went inactive due to personnel changes). The annual investment represents FARE's support of part of the principal investigator's salary and the salary of a full-time research coordinator.New Investigator and Mid-Career AwardsFARE is also committed to markedly increasing the number of investigators in the field through its Investigator in Food Allergy Award Program that was also launched in 2015. The Program is divided into two categories: New Investigator Awards and Mid-Career Awards. The inaugural FARE Investigator in Food Allergy Awards were launched and funded in 2015. FARE launched the second cycle of this program in the Fall of 2016 (and announced recipients in early 2017). The recipients for the first cycle are:2015 New Investigator Recipients ($75K annually for 2 years)1. Jessica O'Konek, PhD, University of Michigan (Ann Arbor) O'Konek will research the modulation of food allergy responses with nanoemulsion-based allergy vaccines, exploring the possibility of providing protection against anaphylaxis with intranasal administration of nanoemulsion combined with egg or peanut antigens.2. Duane Wesemann, MD, PhD, Brigham and Women's Hospital (Boston) Wesemann seeks to identify the extent to which primary Ig repertoires can be influenced by microbial and dietary exposures early in life and examine how modification of these exposures can reduce allergic response to food.Both of these studies will conclude in September 2017.2015 Mid-Career Award Recipients ($150K annually for 5 years)1. Simon Hogan, PhD, Cincinnati Children's Hogan's work focuses on identifying the key proteins and cells that cause the blood vessel fluid leak leading to severe anaphylaxis triggered by foods. This knowledge will have important implications for developing new treatment strategies and therapeutics for preventing the development of severe, life- threatening food reactions.2. Michiko Oyoshi, PhD, Boston Children's Hospital and Harvard Medical School Oyoshi will examine the role of maternal antibodies transferred to babies through breast milk in inducing oral tolerance in children. This study may support potential beneficial effects of maternal allergen exposure during pregnancy and lactation on protecting babies from food allergy.3. Erik Wambre, PhD, Benaroya Research Institute (Seattle) Wambre will investigate the specific T cell responses to peanut allergic components to determine the cellular and molecular mechanism associated with peanut sensitization, as well as those that lead to restoration and maintenance of protective responses.FARE also supports established researchers through funding basic, clinical and epidemiological research at a number of sites across the country.FARE continued its support of the following research studies in 2016 that had been approved in prior years. Please note that FARE's Research Advisory Board (RAB) monitors progress relative to milestones closely for all grant awards.1. The Institute of Medicine (now the National Academies of Science, Engineering and Medicine) completed its project entitled" Food Allergies: Global Burden, Causes, Treatment, Prevention and Public Policy in November 2016. The report, which addresses prevalence, diagnosis and management of food allergy, which FARE lead sponsored, calls for improvements in research, training and public policy to promote the health and well-being of those affected by food allergies.2. Edwin Kim, MD - U. North CarolinaSecond Site: U. Texas Southwest (Drew Bird, MD) Study: Peanut Sublingual Immunotherapy TrialPrevious studies on sublingual immunotherapy (SLIT) and oral immunotherapy (OIT) for peanut have shown that both approaches are able to desensitize most patients to a degree that is likely to prevent allergic reactions after accidental ingestion. However, while SLIT appears to be far safer than OIT, it produces a less robust desensitization effect. The long- term objective of this study is to develop a safe and effective treatment for peanut allergy that will enable patients to develop tolerance. To that end, this study of 48 patients aims to determine whether 36 months of treatment with peanut SLIT will result in clinical tolerance. It also seeks to define the changes in the body's immune system that lead to tolerance. Dr. Edwin Kim and his team hope that this study will provide a strong scientific basis for the development of SLIT and other treatments that aim to produce long-term clinical tolerance to peanuts and other foods. This study is also being conducted at UT Southwestern Medical Center in Dallas.Status: Recruitment ongoing- full recruitment target date: June 20173. Fred D. Finkelman, McDonald Professor of Medicine, Professor of Pediatrics, U. of Cincinnati College of MedicineStudy: Rapid Suppression of Food Allergy with Anti-FCeRIa AntibodySummary: Dr. Finkelman's group at the University of Cincinnati and Cincinnati Children's Hospital published a paper in the June, 2013 issue of the JACI that describes a novel approach for suppressing IgE-mediated allergy: rapid desensitization with an antibody to the high affinity IgE receptor, Fc epsilon RI. The paper showed that this approach could completely suppress IgE-mediated anaphylaxis in mice and that it was longer lasting and less likely to be associated with side effects than rapid desensitization with an allergen.The goal of this proposal is to adapt this approach to people who have IgE-mediated disease, on making it work more rapidly (hours instead of days) and on making it even safer. The approach involves generating and modifying antibodies to human Fc epsilon RI and testing them in 2 sets of humanized mice, one that expresses human Fc epsilon RI instead of mouse Fc epsilon RI; the other that generates human mast cells, basophils and IgE. If successful, this approach could suppress all IgE-mediated disease, including IgE-mediated food allergy, more rapidly and completely than omalizumab and would work even in people who have high levels of IgE.In addition, FARE continued to fund ongoing clinical trials (Wheat, and Walnut OIT) of promising new treatments, as well as epidemiological and basic research. The results of FARE-funded research studies were published in leading peer-reviewed scientific journals, including Allergy & Asthma Proceedings, Annals of Allergy and Immunology, JAMA Pediatrics, the Journal of Allergy and Clinical Immunology, and the Journal of Allergy and Clinical Immunology: In Practice. The results of the following FARE-funded multi-site research studies were presented at 1Q 2016 AAAAI meeting:1. The Avoidance Study (Dr. Gideon Lack Kings College, London)2.Wheat OIT Study (Dr. Hugh Sampson, Mount Sinai School of Medicine)Patient-Centered Outcomes Research Institute --Eugene Washington PCORI Engagement Award ProgramIn May 2016, FARE announced it had received the Eugene Washington Engagement Award from the Patient-Centered Outcomes Research Institute (PCORI).FARE's two-year project, "Empowering Patient Partners and Key Stakeholders to Develop a Patient-Centric Food Allergy Research Program," seeks to address an unmet need in the research field by developing a partnership of patients empowered to work with other key stakeholders, including members of the FARE Clinical Network, to develop a robust patient-centric food allergy research program informed by real- world experiences.FARE is undertaking this initiative at a critical time in food allergy research. The advisory board will influence the process of selecting and prioritizing research and will have input into potential clinical trial designs and endpoints, thus ensuring that patient-reported outcomes are captured.The cornerstone of this project is FARE's new Outcomes Research Advisory Board, which includes four regional 3039984 140992 134574 SEE SCHEDULE Oeducation and advocacy:Education:FARE conducted food allergy education through national, regional, and community- specific efforts. These education programs provided vital information on preventing and managing food allergy reactions, including the life-threatening reaction known as anaphylaxis. FARE's national education initiatives provide information for those living with food allergies, as well as those whose work is impacted by food allergies and the public.In 2016, FARE provided free educational information through its website (foodallergy.org) and blog, maintained an ongoing monthly webinar series on a variety of topics related to food allergy management, and distributed key educational materials such as "Your Food Allergy Field Guide," a comprehensive resource for newly diagnosed patients. FARE also hosted its annual Teen Summit, a national gathering of teens (ages 11-22) with food allergies, along with their parents and siblings; and our National Food Allergy Conference, which brought together individuals and families managing food allergies, caregivers, school staff, and health care professionals -- adding a learning track and continuing education credit for school nurses giving them an opportunity to learn about advances in food allergy research and advocacy, best practices and practical skills for living well with food allergies; and the International Food Allergy & Anaphylaxis Alliance Meeting, which gathers leaders from patient advocacy organizations across the world to inform international policy on food allergy research, education and treatment, advance food allergy awareness, and encourage the commercial sector to support the food allergy community.FARE continued the work of its College Program, doing hands-on training and audits with 36 colleges and university across the country and beginning work on a new tool to provide more detailed and searchable information on accommodations for students with food allergies on college campuses.FARE successfully completed its cooperative agreement with the CDC where we created user-friendly resources, tools and webinars based on the CDC's Voluntary Guidelines for Managing Food Allergies in Schools and Early Care and Education Programs.In 10 pilot communities around the country, FARE created Community Engagement Councils, groups of food allergy healthcare professionals, advocates, families, and volunteers to begin to improve education, outreach, and advocacy efforts locally. FARE also provided community funding awards to local food allergy advocates and leaders to support education and awareness programs in their local communities. These awards again served nearly 1 million people across 50 communities.Advocacy and Public Policy: FARE devoted resources to addressing a range of public policy issues that affect Americans with food allergies and the entities that serve them. FARE continued to provide information and subject matter expertise to the U.S. Congress, Food and Drug Administration, the U.S. Department of Agriculture, the National Institutes of Health, and a variety of professional associations in related fields. FARE led efforts to educate elected officials and key regulators about the impact of high epinephrine auto-injector prices, out of pocket expenses, and other insurance access challenges on members of the food allergy community and worked to highlight solutions to improve competition, innovation, access, and affordability in the epinephrine market. At the state level, FARE has been integral to the passage of laws that allow public entities to stock auto-injectable epinephrine in 30 states, eleven in 2016 alone. We also organized successful food allergy awareness days in four state capitols (Albany, NY, Columbus, OH, Sacramento, CA and Springfield, IL). FARE continued its collaborative efforts with allied professionals by presenting at conferences and working on projects with the National Confectioners Association, the Conference for Food Protection, the Grocery Manufacturers Association, Feeding America, and others. 2194764 SEE SCHEDULE OAWAREness:Through our programs and outreach to media nationwide, FARE heightens awareness of food allergy as a significant and growing public health issue that demands urgent attention. In 2016, FARE's national FARE Walk for Food Allergy program brought together supporters in 40 communities for family-friendly events focused on supporting the food allergy community's cause and increasing awareness of food allergy as a serious public health issue.In May 2016, FARE once again launched its Food Allergy Action Month campaign, which expands the traditional awareness week into an entire month of activities and actions supporters can take to help increase understanding of food allergies and make a positive difference in the lives of those managing the disease.In September and October 2016, FARE raised awareness about food allergies via its high-profile campaign, the Teal Pumpkin Project, designed to promote safety, inclusion and respect of individuals managing food allergies and to keep Halloween a fun, positive experience for all. Resonating with communities across the country and around the world, the Teal Pumpkin Project reached 6.5 million users on Facebook, more than half a million people on Twitter, was covered by hundreds of media outlets, and garnered participation from all 50 states, Washington, D.C., and Puerto Rico. Media coverage of this campaign increased 30 percent over the previous year. In the digital space, FARE's award-winning website and blog received more than 6.4 million page- views in 2016, FARE's bimonthly e-newsletter reached more than 155,000 subscribers with each edition, and FARE's growing social media presence reached millions of users with important information about food allergies and FARE programs.In 2016, FARE issued 161 allergy alerts, which provide information about mislabeled or recalled food, and 12 ingredient notices, which are advance notifications of ingredient changes from food companies. For food allergy families, this is critical information to receive in order to prevent inadvertent reactions. RESEARCH (Con'T):subgroups (Midwest, Northeast Mid-Atlantic, South, and West) and several national advisors. FARE has constituted the Outcomes Research Advisory Board to include patient representatives (parents of children with food allergies or adults with food allergies), researchers, and other stakeholders such as nurses, educators, advocates, health plan payers and pharmacy benefit managers. Working collectively, members of the Advisory Board will help shape food allergy research initiatives by identifying their needs, preferences and priorities for research-based information or evidence. 9079041 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 0 1 0 0 0 0 0 0 0 1 1 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 77 0 1 62 1 1 1 0 0 0 0 1 1 0 0 0 0 X 21 20 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AR CA CO CT FL GA IL KS KY ME MD MA MI MN MS MO NH NJ NM NY NC ND OH OK OR PA RI SC UT VA WA WV WI X X SANDEEP DHAR 7036913179 7925 JONES BRANCH DRIVE SUITE 1100 MCLEAN VA 22102 Janet Atwater Chair 1.00 X X 0 0 0 Rob Nichols Vice-Chair 1.00 X X 0 0 0 Mike Lade Treasurer 1.00 X X 0 0 0 Sharyn Mann Secretary 1.00 X X 0 0 0 Maria Acebal Director 1.00 X 0 0 0 Denise Bunning Director 1.00 X 0 0 0 David Crown Director 1.00 X 0 0 0 Rachael Dedman Director 1.00 X 0 0 0 Andy Gilman Director 1.00 X 0 0 0 John Hannan Director 1.00 X 0 0 0 Joe Ianniello Director 1.00 X 0 0 0 David Jaffe Director 1.00 X 0 0 0 Helen Jaffe Director 1.00 X 0 0 0 Rebecca Lainovic Director 1.00 X 0 0 0 Adam Miller Director 1.00 X 0 0 0 Amie Rappoport-McKenna Director 1.00 X 0 0 0 Joelle Resnick Director 1.00 X 0 0 0 Todd Slotkin Director 1.00 X 0 0 0 Mary Weiser Director 1.00 X 0 0 0 Julie Wilcox Director 1.00 X 0 0 0 James R Baker CEO, CMO 40.00 X X 543960 0 39808 Sandeep Dhar CFO 40.00 X 274168 0 8203 Mary Jane Marchisotto Sr. VP Research 40.00 X 286540 0 10920 Lois Witkop Chieft Advancement Officer 40.00 X 235055 0 8362 Scott Riccio Sr. VP Education and Advoc 40.00 X 268510 0 36314 Lanny BROMFIELD Controller 40.00 X 131992 0 14742 1740225 0 118349 6 0 1 0 The Waldorf Astoria 301 Park Avenue New York NY 10022 Gala Services 278253 Charity Dynamics LLC 3721 Executive Center Dr Suite 100 Austin TX 78731 Consulting 152300 Icahn School of Medicine at Mount Sinai Box 1198 One Gustave L Levy Plac New York NY 100296574 Allergy Research 140000 Stanford University 3160 Porter Drive Palo Alto CA 94304 Allergy Research 129340 Boston Children's Corporation 300 Longwood Avenue Boston MA 02115 Allergy Research 120000 19 104895 3281819 179700 8011568 1891363 11577982 EDUCATIONAL PROGRAMS 900099 134574 134574 Advertising 541800 25000 25000 159574 60269 60269 33810 0 33810 33810 33810 42478640 47485577 -5006937 -5006937 -5006937 340896 3281819 911707 -570811 -570811 47150 14465 32685 32685 100700 21310 79390 79390 OTHER INCOME 900099 4284 4284 4284 6370246 213964 25000 -5446700 2859993 2859993 13435 13435 1733880 1241246 154757 337877 3144563 2256902 280688 606973 97216 69412 8626 19178 326419 222499 29173 74747 314381 225223 28393 60765 54839 458 36500 17881 31408 12793 9249 9366 30050 30050 137000 137000 675672 602128 -51715 125259 319982 134282 345 185355 496732 306352 16954 173426 465944 205528 81028 179388 418468 229075 109681 79712 394928 309857 17146 67925 35847 19046 10710 6091 91962 48862 27475 15625 bank fees 192964 113419 3427 76118 MISC. EXPENSES 70264 69859 228 177 Mail Shop Fees 22682 1672 300 20710 11928629 9079041 793015 2056573 X 1170298 759438 0 410860 3035347 2710529 11421870 52224765 1310369 1841234 30630 12160 24230 29967 95778 178426 209353 147215 97984 62138 47485577 0 29555 31521 63531340 57090740 708490 817518 5604373 4639600 121163 94691 6434026 5551809 X 52302888 45031650 4794426 6507281 57097314 51538931 63531340 57090740 -5558383 0 X X 0 1 X 1 0 X 8817983 15724060 13005978 12086613 11577982 61212616 8817983 15724060 13005978 12086613 11577982 61212616 13963963 47248653 24100 15222 7932 25847 94079 167180 61379796 1137053 0.76980 0.79330 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 99500 99500 12776610 12876110 793806 198452 0 0 779300 739676 1000000 793806 3312782 4969173 321000 152250 94125 99500 666875 194825 184919 250000 198452 828196 1242294 16547 10243 6304 179276 123442 55834 13530 13530 0 62138 DEFERRED RENT 94691 94691 7317727 947482 947482 6370245 0 6370245 12876110 947482 947482 11928628 0 11928628 Part XI, Line 2d - Other Adjustments: COST OF GOODS SOLD 21,310. DIRECT FUNDRAISING EXPENSES 926,172. Part XII, Line 2d - Other Adjustments: COST OF GOODS SOLD 21,310. DIRECT FUNDRAISING EXPENSES 926,172. GALA 2152371 2084871 67500 278253 50738 148034 LUNCH 793729 645929 147800 36437 96453 128510 13 676615 551019 125596 42263 131019 3622715 3281819 340896 314690 189454 407563 911707 -570811 47150 14465 1 0.85000 47150 14465 14465 32685 NY 1 0 1 0 1.00000 ANNE HORNING 515 MADISON AVENUE SUITE 1912 NEW YORK NY 10022 0 0 1 ACHRI Lee Smith 13 Childrens Way Slot 842 842 Little Rock AR 72202 710694931 501 ( c ) 3 120000 Fare Clinical Network Anaphylaxis & Food Allergy Assn of MN (AFAA) 2200 Hendon Avenue St Paul MN 55108 050585572 501 ( c ) 3 9100 Education grants Baylor College of Medicine 1 baylor Plaza Houston TX 77030 741613878 501 ( c ) 3 70000 Fare Clinical Network Benaroya Research Institute at Virginia Mason 1201 Ninth Avenue Seattle WA 98101 910653422 501 ( c ) 3 70000 Fare Clinical Network Boston Children's Corporation 300 Longwood Avenue Boston MA 02115 042774441 501 ( c ) 3 120000 Fare Clinical Network Children's Hospital Los Angeles Div Of Clinical Immunology Allergy Dept of Pediatrics Los Angeles CA 90027 951690977 501 ( c ) 3 70000 Fare Clinical Network Children's Hospital of Pittsburgh Foundation Central Plant Floor 34401 Penn Ave Pittsburgh PA 15224 251865744 501 ( c ) 3 8575 Education grants Children's Hospital of Pittsburgh of UPM 4401 Penn Avenue Pittsburgh PA 152241334 250402510 501 ( c ) 3 120000 Fare Clinical Network Children's National 111 Michigan Ave NW Washington DC 20010 521640403 501 ( c ) 3 70000 Fare Clinical Network cincinnati Children's Hospital Medical Center 3333 Burnet Avem ML 7030 Cincinnati OH 452293039 310833936 501 ( c ) 3 120000 Fare Clinical Network Columbia University Medical Center 630W 138th Street New York NY 10032 135598093 501 ( c ) 3 70000 Fare Clinical Network Food Allergy Education Network P O Box 286 Brandford CT 06405 451668175 501 ( c ) 3 5786 Education grants Icahn School of Medicine Box 1198 One Gustave L Levy Place New York NY 100296574 136171197 501 ( c ) 3 140000 Fare Clinical Network Indiana University 11725 N Illinois Street Carmel IN 46032 356001673 501 ( c ) 3 70000 Fare Clinical Network Lurie Children's Hospital of Chicago 225 E Chicago Ave Chicago IL 60611 362170833 501 ( c ) 3 120000 Fare Clinical Network Massachusetts General Hospital 175 Cambridge Street Boston MA 02114 042697983 501 ( c ) 3 120000 Fare Clinical Network National Jewish Health 1400 Jackson Street Denver CO 80206 742044647 501 ( c ) 3 120000 Fare Clinical Network Northwest Allergy and Asthma Center 9725 3rd Ave NE Suite 500 Seattle WA 98115 237219813 501 ( c ) 3 70000 Fare Clinical Network Rady Children's Hospital University of California 9500 Gilman Drive 0934 La Jolla CA 92093 956006144 501 ( c ) 3 120000 Fare Clinical Network Regents of the University of Michigan 500 S State St Ann Arbor MI 48109 386006309 501 ( c ) 3 70000 Fare Clinical Network Specially for Children 1345 Philomena Street Austin TX 78723 742800601 501 ( c ) 3 70000 Fare Clinical Network Stanford University 3160 Porter Drive Palo Alto CA 94304 911156365 501 ( c ) 3 129340 Fare Clinical Network The Children's Hospital of Philadelphia 3401 Civic Center Blvd Philadelphia PA 19104 231352166 501 ( c ) 3 120000 Fare Clinical Network The Children's Mercy Hospital 2401 Gillham Rd Kansas City MO 64108 440605373 501 ( c ) 3 70000 Fare Clinical Network The University of Chicago 5801 S Ellis Ave Chicago IL 60637 362177139 501 ( c ) 3 70000 Fare Clinical Network University of Arizona PO Box 210017 Tuscon AZ 85721 742652689 501 ( c ) 3 78440 Fare Clinical Network University of California-LA 110000 Kinross Avenue Los Angeles CA 90095 956006143 501 ( c ) 3 70000 Fare Clinical Network University of Colorado Mail Stop F428 Aurora CO 80045 846000555 501 ( c ) 3 120000 Fare Clinical Network University of North Carolina at Chapel Hill 260 MacNider CB7220 Chapel Hill NC 27599 566001393 501 ( c ) 3 120000 Fare Clinical Network University of Texas Southwestern Medical Center 5323 Harry Hines Blvd Dallas TX 75390 756002868 501 ( c ) 3 120000 Fare Clinical Network University of Utah 332 South 1400 East Suite 150 Salt lake City UT 84112 876000525 501 ( c ) 3 70000 Fare Clinical Network Utah Food Allergy Network PO Box 711246 Salt Lake City UT 84171 208914771 501 ( c ) 3 5400 Education grants 32 0 EDUCATION 2 13435 Part I, Line 2: THERE IS A FORMAL GRANT REVIEW PROCESS. ALL DISBURSEMENTS ARE DOCUMENTED. GRANTEES ARE REQUIRED TO WRITE ANNUAL UPDATES ON THEIR PROGRESS AS WELL AS GOALS ACHIEVED. FUTURE GRANT AWARDS ARE CONTINGENT UPON ACHIEVEMENT OF SPECIFIC MILESTONES. X X X 0 0 0 0 0 0 0 1 0 James R Baker CEO, CMO 501866 0 40000 0 2094 0 9450 0 39166 0 592576 0 0 0 Sandeep Dhar CFO 238438 0 35000 0 730 0 8203 0 1608 0 283979 0 0 0 Mary Jane Marchisotto Sr. VP Research 259446 0 25000 0 2094 0 8632 0 4340 0 299512 0 0 0 Lois Witkop Chieft Advancement Officer 219565 0 15040 0 450 0 7050 0 3423 0 245528 0 0 0 Scott Riccio Sr. VP Education and Advoc 249713 0 18480 0 317 0 8290 0 35483 0 312283 0 0 0 Part I, Line 7 BONUSES ARE PROVIDED TO ENSURE THAT KEY EMPLOYEES WHO PERFORM WELL ARE RECOGNIZED FOR THEIR PERFORMANCE AND RETAINED BY FARE. THE PERFORMANCE OF THESE EMPLOYEES WAS REVIEWED BY MANAGEMENT, INCLUDING THE CEO, AND BONUSES WERE AWARDED APPROPRIATELY. OTHER REPORTABLE COMPENSATION INCLUDES SEVERANCE PAY, RELOCATION, AND TRANSITION COSTS. X 3575 X 17958 1839843 FMV X VACATION PACKAGES 8 13900 FMV X OTHER MISCELLANEOUS 12 12981 FMV X FOOD/RESTAURANT GIFT CERT 19 9638 FMV X FASHION/BEAUTY PACKAGES 15 5686 FMV X SPORTS/SHOWS 7 2535 FMV X FITNESS/GYM 5 2035 FMV X jewelry 3 1170 FMV 0 0 0 0 Form 990, Part VI, Section B, line 11b a DRAFT OF FORM 990 IS SENT TO THE BOARD FOR REVIEW BEFORE IT IS FILED WITH THE IRS. Form 990, Part VI, Section B, line 12c ALL STAFF, BOARD MEMBERS, OFFICERS AND TRUSTEES ANNUALLY SIGN A FOOD ALLERGY RESEARCH & EDUCATION MANAGEMENT AND STAFF DISCLOSURE STATEMENT WHICH AFFIRMS THAT THEY HAVE RECEIVED A COPY OF THE CONFLICT OF INTEREST POLICY, HAVE READ AND UNDERSTAND IT, AND HAVE AGREED TO COMPLY WITH THE POLICY. IF A CONFLICT OF INTEREST IS DISCLOSED, THE AFFECTED PARTY WILL DISCUSS THE ISSUE WITH THE BOARD OF DIRECTORS. THE BOARD OF DIRECTORS WILL DISCUSS THE ISSUES, CONSULT AN ATTORNEY IF NECESSARY, AND TAKE APPROPRIATE ACTION. APPROPRIATE DISCIPLINARY ACTION WILL BE IMPOSED AGAINST ANY PERSON VIOLATING THE POLICY. Form 990, Part VI, Section B, line 15 THE ORGANIZATION USES COMPARABLE DATA IN THE INDUSTRY TO DETERMINE COMPENSATION AND COMPENSATION IS VOTED AND AGREED UPON BY THE GOVERNING BODY. Form 990, Part VI, Section C, line 19 THE ORGANIZATION'S FINANCIAL STATEMENTS ARE AVAILABLE ON THE ORGANIZATION'S WEBSITE. ANY OTHER DOCUMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART XII, LINE 2C THE AUDIT OVERSIGHT PROCESS HAS REMAINED UNCHANGED FROM THE PRIOR YEAR.